Precision BioSciences, Inc. (DTIL) Social Stream

Precision BioSciences, Inc. (DTIL): $10.64

-0.21 (-1.94%)

POWR Rating

Component Grades













Add DTIL to Watchlist
Sign Up

Industry: Biotech


of 486

in industry

Featured Post From StockTwits About DTIL

$DTIL $VERV is either extremely overvalued OR PBI is extremely undervalued.

To illuminate massive discount since this company doesn’t have a buzz word such as “CRISPR” in it - Verve, that relies on beam therapeutics base editor is being valued at $811 million based on their IPO pricing.

IF PBI went ahead with their program - they’d be further along with the pre clinical studies! (Since first is POC , then animal testing etc etc)

Lily commented with Dr. Jantz wanting to develop such a medication that can be hugely preventive -/ So you can buy PBIs PKS9 program (not in development YET) for free based on verve valuation and in the interim you get 4 car-t clinical trials + one pending IND (so hopefully a 5th trial) and if any joy with the collaboration with Lilly we could see a 6th with DMD (& targets 7 and 8 disclosed) —
MaK613, published June 18, 2021

What Else are DTIL Traders Talking About?

Other tickers frequently mentioned alongside DTIL are OCGN and CRSP.

Other Notable StockTweets About DTIL

$OCGN BioGenerator-supported Precision Virologics’ novel vaccine candidate advances to human trials in St. Louis and India
ST. LOUIS – Biotech startup Precision Virologics, $DTIL which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a manufacturing giant of vaccines, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets.

The licensing agreements for Precision Virologics and Bharat Biotech will lead to rapid clinical development, following the intranasal vaccine candidate having shown unprecedented levels of protection in mouse studies. This technology and data recently was published in scientific journal Cell and in an editorial in Nature.

DevilDocTX, published June 11, 2021

CRISPR 101: What Investors Need to Know | The Motley Fool

“Anand Chokkavelu, CFA has no position in any of the stocks mentioned. Brian Orelli, PhD owns shares of Precision BioSciences Inc. Matthew Frankel, CFP has no position in any of the stocks mentioned.”

This say it all - the person interviewed Dr. Orelli only owns one company in this article - $DTIL

His statement neither bearish or bullish is factually true and clearly he must not agree with Mr. Market

Otherwise you’d see $CRSP in the disclosure instead of $DTIL

MaK613, published June 6, 2021

$DTIL Whoa - shorts loaded back up. Still approx 1 mill share bought back since peak levels of 7m+

This doesn't include some private lenders - but those don't actually effect the free float. Since these #s are also based on private loans that are not bought or sold into the actual market.

For example Interactive Brokers has customers with say 1,000,000 shares of $DTIL they can utilize those shares as collateral for shorts.

Let's assume all accounts allow short lending for collateral. So they (IBKR) will lend DIRECTLY to the person trying to short without needing to sell into the open market. So this is beneficial as if they shorted 1million shares - zero would be actually sold into the market.

IMO these types of short positions do not benefit long holders from a squeeze, since they don't need to buy back the shares in the open market they just close out the loan. Of course, customers can sell shares before a cover making IBKR need to purchase in the open market

MaK613, published June 3, 2021

Dr. James Wilson Ph.D., MD earlier this week was asked straight out regarding their collaboration with $DTIL Question ARCUS VERSUS CRISPR/Cas9 and "other methods"

Moderator Alex Philippidis asks:

"To follow up on one at least one of the collaborations your lab is working with, Precision Biosciences they have a proprietary gene-editing platform called ARCUS. What are the Pros & Cons of that technology compared to CRISPR/Cas9 or other Methods?"

Answer By James Wilson:
"Well when we decided we would get into the editing space we actually did a fair amount of CRISPR with AAV and also LNP delivery and also the technology out of Precision which are meganuclease and it simply just worked a lot better, I don't know why. It was much, much more efficient & it's very small so it can be accommodated in vectors"

I Will be posting a link shortly for those who don't have time to watch the entire presentation with the video excerpt of the Q&A by Alex and Dr. Wilson

MaK613, published May 19, 2021

Loading social stream, please wait...

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5259 seconds.